What is the recommended treatment for a patient with invasive mucinous adenocarcinoma of the appendix (T3) after appendectomy, with tumor invasion through the muscularis propria into the subserosa and mesoappendix but no serosal involvement?

Treatment for Invasive Mucinous Adenocarcinoma of the Appendix (T3)

Right hemicolectomy is the recommended definitive surgical treatment for T3 invasive mucinous adenocarcinoma of the appendix following initial appendectomy, as appendectomy alone is insufficient for adequate oncologic resection and staging. 1, 2

Surgical Management Algorithm

Completion Right Hemicolectomy is Indicated

For T3 mucinous adenocarcinoma (tumor invading through muscularis propria into subserosa/mesoappendix without serosal involvement), right hemicolectomy should be performed to achieve:

• Adequate lymph node harvest (minimum 12 lymph nodes) for accurate staging, as nodal metastases occur in approximately 20% of patients despite lower rates than non-mucinous adenocarcinomas 3, 1
• Wide resection margins with en bloc colonic and mesentery resection to define stage II versus stage III disease 3
• Complete oncologic resection given that appendectomy alone provides inadequate margins and lymph node assessment 2

Key Pathologic Risk Factors to Assess

The following features from your pathology report determine prognosis and guide adjuvant therapy decisions:

• Tumor grade/differentiation: Well-differentiated T3 tumors have only 7% nodal metastasis risk, while poorly differentiated tumors carry significantly higher risk 1
• Lymphovascular invasion: Presence indicates higher risk and influences adjuvant therapy decisions 3
• Surgical margin status: Positive margins (<1 mm) require re-excision 3
• Presence of acellular mucin on serosa: This is a risk factor for pseudomyxoma peritonei development 4
• Appendiceal perforation status: Perforation increases risk of peritoneal dissemination 4

Adjuvant Therapy Considerations

For Stage II Disease (T3N0)

If final pathology after right hemicolectomy confirms node-negative disease, adjuvant chemotherapy decisions should integrate:

• Tumor grade and high-risk features (lymphovascular invasion, inadequate lymph node sampling <12 nodes, poorly differentiated histology) 3
• Consider gastrointestinal-type regimens (FOLFOX, capecitabine/oxaliplatin) as mucinous appendiceal adenocarcinomas share biological similarities with gastrointestinal tumors 3, 5
• Observation is reasonable for well-differentiated T3 tumors without high-risk features 3

For Stage III Disease (Node-Positive)

Adjuvant chemotherapy is recommended using either:

• Standard colorectal cancer regimens (carboplatin/paclitaxel or docetaxel) 3
• Gastrointestinal-type regimens (FOLFOX or capecitabine/oxaliplatin) given the mucinous histology 3, 5

Surveillance and Follow-Up

Post-treatment surveillance should include:

• Colonoscopy at 1 year post-resection, then every 3-5 years if normal 3
• Serial CEA measurements every 3-6 months for 2 years, then every 6 months for years 3-5 3
• CT imaging of chest/abdomen/pelvis every 6-12 months for 5 years to monitor for peritoneal recurrence, given the propensity for peritoneal dissemination in mucinous adenocarcinomas 5, 6

Critical Pitfalls to Avoid

• Do not rely on appendectomy alone for T3 disease—this provides inadequate staging and oncologic resection 1, 2
• Ensure adequate lymph node harvest (≥12 nodes) as inadequate sampling is a high-risk feature requiring consideration of adjuvant therapy 3
• Monitor for pseudomyxoma peritonei development, particularly if acellular mucin was present on serosa or if appendiceal perforation occurred 4, 6
• Consider cytoreductive surgery with HIPEC only if peritoneal disease develops during surveillance, not as primary treatment for localized T3 disease 6, 7